A5087358273- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Nanoparticle-Based Drug Delivery
- Histone Deacetylase Inhibitors Research
- Graphene and Nanomaterials Applications
- Cancer Genomics and Diagnostics
- Medical Imaging Techniques and Applications
- Nanowire Synthesis and Applications
- Advanced biosensing and bioanalysis techniques
- Genetic factors in colorectal cancer
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Viral-associated cancers and disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer therapeutics and mechanisms
Boston Children's Museum
2021-2024
Boston Children's Hospital
2021-2024
Harvard University
2022-2024
University of Turin
2012-2021
Abstract Introduction: Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) have extended the survival of patients with ALK-rearranged cancers, including non-small cell lung cancer (NSCLC). Unfortunately, acquired resistance develops within 2-3 years, highlighting urgent need for novel and effective therapeutic strategies these patients. Here, we aimed to identify T receptor (TCR) clonotypes against two human ALK immunogenic peptides previously identified by mass spectrometry...
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B-cell malignancies, but many patients relapse due to failed expansion and/or progressive loss of CAR-T cells. We recently reported a strategy potently restimulate cells vivo, enhancing their functionality by administration vaccine-like stimulus comprised surrogate peptide ligands for CAR linked lymph node-targeting amphiphilic PEG-lipid (termed CAR-T-vax). Here, we demonstrate general...
Abstract Neuroblastoma is the most common extracranial solid tumor of childhood, with limited success in treating refractory or relapsed cases using current therapies. Chimeric antigen receptor (CAR) T cell therapy targeting GD2 has shown promise neuroblastoma treatment, but relapses are associated loss expression. The selection best critical for therapeutic CAR-T cells hematologic malignancies and tumors. Anaplastic Lymphoma Kinase (ALK) expressed by neuroblastomas while virtually absent...
<h3>Background</h3> Although the development of ALK tyrosine kinase inhibitors (TKIs) has significantly improved clinical outcomes in patients with Anaplastic Lymphoma Kinase (ALK)-rearranged tumors, including non-small cell lung cancers (NSCLCs) and anaplastic large lymphoma (ALCL), acquired resistance inevitably develops within 2–3 years, limiting survival these patients. Here, we aimed to identify T receptor (TCR) clonotypes targeting two human immunogenic peptides presented by...
Recent studies reported the expression of anaplastic lymphoma kinase (ALK) in malignant melanomas. The aim this study was to investigate whether ALK is associated with specific clinical and molecular characteristics melanoma metastases, evaluate its correlation survival outcomes. Seventy‑one patients metastatic were investigated. Clinical features outcomes analyzed correlated expression, as detected by immunohistochemistry reverse transcription‑quantitative polymerase chain reaction,...
Abstract The introduction of proteasome inhibitors (PIs) into the clinic has transformed treatment patients affected by multiple myeloma (MM) and mantle-cell lymphoma (MCL) establishing new standards care. Despite these improvements, continuously relapse or are intrinsically resistant to PIs. Here, identify druggable targets that synergize with PIs, we carried out a functional screening in MM cell lines using short hairpin RNA library targeting 152 cancer driver genes, highly representative...
The ubiquitin-proteasome pathway plays a crucial role in protein processing and degradation, it regulates critical cellular functions. Proteasome inhibitors (PIs) are extensively used for the therapy of multiple myeloma (MM) mantle-cell lymphoma (MCL). However, patients continuously relapse or intrinsically resistant to this class drugs. We have previously identified isocitrate dehydrogenase 2 (IDH2) as synthetic lethal target that synergizes with PI carfilzomib (CFZ). Here, we demonstrate...
<h3>Background</h3> Neuroblastoma is the most common extracranial solid tumor of childhood<sup>1</sup> and accounts for 12-15% cancer-related deaths in children.<sup>2</sup> The survival patients with refractory or relapsed neuroblastoma remains dismal.<sup>3</sup> In neuroblastoma, chimeric antigen receptor (CAR) T cells against GD2 have shown encouraging clinical results, but relapses are associated loss expression. selection best target critical therapeutic success CAR-T hematologic...
Abstract Neuroblastoma (NB) is the most deadly cancer in children with dismal survival high-risk patients. The majority of NB express full length anaplastic lymphoma kinase (ALK) receptor, that typically acts as driver oncogene together MYCN. In contrast to ALK-driven lung or lymphoma, targeted therapies ALK tyrosine inhibitors (TKIs), despite encouraging, induce only partial responses NB. Therefore, additional tools improve treatment are strongly needed. To specifically target cells, we...